Ankylosing spondylitis
Conference Coverage
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...
Latest News
First referral guide issued for axial spondyloarthritis
The draft recommendations are a “good first step,” but more awareness around axial spondyloarthritis in the nonrheumatology community is also...
Conference Coverage
TNF blockers not associated with poorer pregnancy outcomes
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal...
News from the FDA/CDC
Approximately 20% of U.S. adults are diagnosed with arthritis
New data show disproportionate arthritis prevalence among women, veterans, non-Hispanic White individuals, and those aged 45 years and older.
From the Journals
Anemia, iron deficit common in rheumatic disease pregnancy
Low maternal levels of hemoglobin and serum ferritin in pregnancy were associated with adverse infant outcomes.
Conference Coverage
Are women and men with rheumatism treated equally?
Compared with men, women receive a diagnosis of rheumatic disease much later and are treated more poorly, research suggests.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
From the Journals
Mortality in ankylosing spondylitis: CV disease, drug abuse are big contributors
Heart failure and renal disease were the strongest contributing comorbidities to mortality in hospitalized patients with ankylosing spondylitis....
From the Journals
Fracture risk factors described in patients with ankylosing spondylitis
Individuals with a history of fracture were five times more likely to develop an additional fracture.
Latest News
Rheumatology trials seem vulnerable to unblinding: Report
In an analysis of 14 published randomized controlled clinical trials of common rheumatology drugs, most had a high estimated risk for inadvertent...